Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Allarity holds global, exclusive rights to the PARP inhibitor, Stenoparib, under an existing license with Eisai, in the field of cancer therapeutics and treatment. With the amendment, Allarity now further holds global, exclusive rights to the drug as an anti-viral therapy.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Allarity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2020
Details:
Sosei Heptares has successfully designed three distinct series of compounds. These compounds have demonstrated high potency in inhibiting the activity of the Mpro protease as well as promising oral bioavailability and blood plasma levels in animal studies.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Governor Ogawa confirmed the effectiveness of the "nucleic acid drug" against viral infections in an experiment using a new coronavirus strain, and finished narrowing down to three types of drug candidates that could be expected to be effective even in small amounts.
Lead Product(s): BNC-1322
Therapeutic Area: Infections and Infectious Diseases Product Name: BNC-1322
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow.
Lead Product(s): Eritoran
Therapeutic Area: Infections and Infectious Diseases Product Name: E5564
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: The Global Coalition for Adaptive Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 01, 2020
Details:
Daiichi Sankyo is set to develop a mRNA vaccine candidate to protect against Covid-19 infection in the country. The project, Fundamental Research on the Control of a Novel Coronavirus (2019-nCoV), is supported by the Japan Agency for Medical Research and Development (AMED).
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Physicians from Keck Medicine of USC are set to launch a clinical trial to study the effects of an anti-inflammatory drug on treating patients with moderate to severe coronavirus (Covid-19).
Lead Product(s): Synthetic human antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
